Select your country
Websites worldwide
Select a country to go to the website of the respective STADA sales company.
Australia (1)
Austria (1)
Belarus (1)
Belgium (1)
Bosnia-Herzegovina (1)
Bulgaria (1)
China (1)
Croatia (1)
Czech Republic (2)
Denmark (1)
France (1)
Hungary (1)
Ireland (1)
Italy (1)
Montenegro (1)
Netherlands (2)
Poland (1)
Portugal (1)
Romania (1)
Serbia (1)
Slovakia (1)
Slovenia (1)
Spain (1)
Switzerland (1)
Thailand (1)
The Phillippines (1)
United Kingdom (3)
Vietnam (2)
STADA Sets Stage at Key Biosimilars Event
STADA‘s Dr Christine Berndt, Vice President Global Specialty Development and Chair of Medicines for Europe’s Biosimilar Medicines Sector Group, outlined the opportunities and challenges for Europe‘s biosimilars sector during the opening speech to around 250 delegates at Medicines for Europe‘s Biosimilar Medicines (BIOS26) Conference held in Amsterdam, the Netherlands, on 7–8 May.
Addressing physicians, hospital pharmacists, payers, regulators, policy makers, patient groups, as well as STADA‘s existing and potential biosimilar development and manufacturing partners, Christine highlighted the significant progress made across the biosimilars sector over the past two decades.
20 Years of Biosimilars: Supporting Access and Sustainable Healthcare
Speaking 20 years after the approval of the first biosimilar in Europe, she highlighted that biosimilars have become an established part of healthcare systems. She noted that they can play an important role in supporting broader access to treatment options and contributing to the sustainability of healthcare systems.
She also emphasized the importance of collaboration, partnership and supportive policy frameworks across the healthcare ecosystem to further strengthen healthcare resilience, support Europe’s global competitiveness and enable future biosimilar success.
